Public Health and Prescription Overdose Prevention, Monitoring, Enforcement and Treatment
Tuesday, November 5, 2013: 4:30 p.m. - 6:00 p.m.
In 2006, the estimated total cost of nonmedical use of prescription opioids was $53.4 billion and, exacerbating the problem, drug overdose death rates in the United States have more than tripled since 1990 and have never been higher. Research indicates that poisoning surpassed motor vehicle crashes as the leading cause of injury death in the United States in 2008. In the past three decades, the percentage of poisoning deaths caused by drugs increased from about 60% to about 90%. While the majority of these deaths were unintentional, opioid analgesics were involved more frequently than other specified drugs, including heroin and cocaine, representing a critical opportunity for federal and state agencies, together with a broad network of partners, to identify and employ strategies focused on preventing the inappropriate use and diversion of prescription drugs.
Working with five states, the Association of State and Territorial Health Officials (ASTHO) developed a state learning community model to address prescription drug overdose misuse, abuse and diversion. The model addresses prevention, monitoring, enforcement, treatment and recovery as issues that states should act upon comprehensively rather than in silos. Working with state public health agencies and partners across all sectors utilize the ASTHO state health policy and practice recommendations matrix developed from the White House ONDCP and CDC national guidelines to develop and implement a comprehensive action plan. In Oklahoma, by collaborating with state partners, built upon a state task force to develop a comprehensive state plan and collaborate more effectively with enforcement and monitoring systems in the state.
In this panel session, ASTHO, the state Commissioner of Health of Oklahoma, and the National Association of State Alcohol and Drug Abuse Directors (NASADAD) will describe how state public health agencies work across sectors and with our treatment and recovery partners to take a comprehensive approach to prescription drug control.
Session Objectives: Demonstrate state health agency’s role in partnership to address prescription drug abuse.
Identify key recommendations for the role of public health and public health agencies in the key areas of prevention, PDMP’s, enforcement, and treatment of prescription drug overdose misuse and diversion.
See individual abstracts for presenting author's disclosure statement and author's information.
Organized by: Alcohol, Tobacco, and Other Drugs
Endorsed by: Epidemiology, Chiropractic Health Care
Medical (CME), Health Education (CHES), Nursing (CNE), Public Health (CPH)